Septerna (NASDAQ:SEPN) Coverage Initiated at Cantor Fitzgerald

Cantor Fitzgerald assumed coverage on shares of Septerna (NASDAQ:SEPN - Free Report) in a report published on Tuesday morning, MarketBeat.com reports. The firm issued an overweight rating and a $50.00 price objective on the stock.

Separately, TD Cowen started coverage on Septerna in a report on Tuesday. They set a "buy" rating on the stock.

Septerna Trading Up 2.4 %

NASDAQ:SEPN traded up $0.57 during trading hours on Tuesday, reaching $24.12. 185,032 shares of the company traded hands, compared to its average volume of 199,049. Septerna has a 1-year low of $18.62 and a 1-year high of $26.34.

Insiders Place Their Bets

In other Septerna news, major shareholder Rock Ventures V. L.P. Third purchased 370,500 shares of Septerna stock in a transaction on Monday, October 28th. The shares were bought at an average price of $18.00 per share, with a total value of $6,669,000.00. Following the purchase, the insider now directly owns 6,215,591 shares in the company, valued at $111,880,638. This trade represents a 6.34 % increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Septerna Company Profile

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.